Fulcrum Therapeutics (FULC) Retained Earnings (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Retained Earnings for 9 consecutive years, with -$639.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Retained Earnings fell 15.33% year-over-year to -$639.3 million; the TTM figure through Jun 2026 stood at -$639.3 million (down 15.33% YoY), while the FY2025 annual figure was -$594.3 million, down 14.42% from the prior year.
• Retained Earnings declined to -$639.3 million in Q2 2026 per FULC's latest filing, from -$613.2 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$328.4 million in Q1 2022 and bottomed at -$639.3 million in Q2 2026.
• Historically, Retained Earnings has averaged -$496.3 million across 5 years, with a median of -$506.3 million in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings sank 40.34% — and 2025, when it declined 0.1%.
• Fulcrum Therapeutics' Retained Earnings stood at -$412.3 million in 2022, then fell by 23.61% to -$509.7 million in 2023, then slipped by 1.91% to -$519.4 million in 2024, then slipped by 14.42% to -$594.3 million in 2025, then fell by 7.58% to -$639.3 million in 2026.
• Business Quant data shows FULC's Retained Earnings at -$639.3 million in Q2 2026, -$613.2 million in Q1 2026, and -$594.3 million in Q4 2025.